Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Erlotinib - Astellas Pharma/Roche

Drug Profile

Erlotinib - Astellas Pharma/Roche

Alternative Names: CP-358774; CP-358774-01; Erlotinib hydrochloride; NSC-718781; OSI-774; R-1415; RG-1415; RO-508231; Ro50-8231; Tarceva

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OSI Pharmaceuticals
  • Developer Alliance for Clinical Trials in Oncology; Astellas Pharma; Chugai Pharmaceutical; Eli Lilly and Company; European Thoracic Oncology Platform; Finnish Lung Cancer Group; Genentech; M. D. Anderson Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Novartis; OSI Pharmaceuticals; Polyphenon Pharma; Roche; SCRI Development Innovations; Takeda Oncology; University of Texas M. D. Anderson Cancer Center; Wake Forest University School of Medicine
  • Class Alkynes; Antineoplastics; Quinazolines; Skin disorder therapies; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer; Pancreatic cancer
  • Phase III Ependymoma; Head and neck cancer; Mouth neoplasm
  • Phase II Bladder cancer; Brain metastases; Glioblastoma; Gynaecological cancer; Neuroendocrine tumours; Squamous cell cancer
  • Phase I/II Colorectal cancer; Myelodysplastic syndromes; Solid tumours
  • No development reported Anaplastic astrocytoma; Breast cancer; Bronchiolo-alveolar adenocarcinoma; Cancer metastases
  • Discontinued Liver cancer

Most Recent Events

  • 07 Dec 2022 University of Texas M. D. Anderson Cancer Center and Millenium Pharmaceuticals complete a phase I trial in Solid tumours, Non-small cell lung cancer, Pancreatic cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT02942095)
  • 26 Apr 2022 No development reported - Phase-III for Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Bulgaria, Italy, Germany, Belgium, Sweden, USA (PO)
  • 19 May 2021 The MD Anderson Cancer Center and Genentech completes a phase II trial for Liver cancer (Inoperable/Unresectable, Combination therapy, Second-line therapy or greater) in USA (NCT01180959)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top